Company in the news: AstraZeneca
Drugs giant AstraZeneca is at the centre of a takeover tussle with US rival Pfizer. Phil Oakley looks at how the shares have been affected.
The stock market can be a funny place. Less than a year ago shares in AstraZeneca (LSE: AZN)were changing hands for just over £30 per share.
The company was seen as one of the weakest players in the global pharmaceutical industry, facing years of declining sales and profits as some of its blockbuster drugs came off patent and became exposed to competition from cheap generic ones.Yet value is often in the eye of the beholder.
US drug giant Pfizer has had two bids (the latest being tabled at £50 per share) for AstraZeneca rejected, because the management said that it undervalued the firm.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
AstraZeneca has been talking up the value of its drugs pipeline in development. It reckons that new drugs to treat cancer, diabetes and Alzheimer's, among others, could see its sales grow by 75% by 2023.
Given that these drugs have not yet seen the light of day in terms of regulatory approval, let alone sales and profits, this sounds like a valiant attempt to get Pfizer to pay up. But will it?
Maybe. Pfizer has a reputation for growing by buying other companies, rather than by making its own drugs.On top of that it strips out costs and boosts profits. It would seem that the time for Pfizer to do this again has arrived, hence its interest in AstraZeneca.
Pfizer's own sales are falling, because its big earning drugs, such as Lipitor and Viagra, are attracting fierce competition. It seems that Pfizer can chop a lot of costs out ofAstraZeneca but that there is also abigger prize of moving its headquartersto the UK and paying lower taxes than itdoes in America.
The UK government is under pressure tostop Pfizer sacking lots of highly trainedscientists and damaging the country'sscience base. The American governmentwill be keen to stop a big taxpayer likePfizer moving to Britain.
Pfizer has until 26 May to get its bidaccepted. If it does not, it will have toincrease it or pursue a hostile takeover. Should the deal fail, thenyou have to ask whether AstraZeneca'sshares are worth their current £46. That would put it on 18.5 times forecastearnings, compared with 15.3 timesfor the more highly regarded GlaxoSmithKline.
A year ago AstraZenecashares were probably too cheap, butbuying them now looks more risky.Existing shareholders should sit tight,but don't buy if you haven't already.
Verdict: hold
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Phil spent 13 years as an investment analyst for both stockbroking and fund management companies.
After graduating with a MSc in International Banking, Economics & Finance from Liverpool Business School in 1996, Phil went to work for BWD Rensburg, a Liverpool based investment manager. In 2001, he joined ABN AMRO as a transport analyst. After a brief spell as a food retail analyst, he spent five years with ABN's very successful UK Smaller Companies team where he covered engineering, transport and support services stocks.
In 2007, Phil joined Halbis Capital Management as a European equities analyst. He began writing for MoneyWeek in 2010.
-
Do you qualify for the Winter Fuel Payment if you live abroad?
The Winter Fuel Payment will be means tested for expats living in Europe, in line with the new rules impacting those in the UK. But a quirk in the system means not all countries are eligible.
By Katie Williams Published
-
What the Employment Rights Bill means for your job
New workplace reforms are set to give employees new rights to benefits and flexible working
By Marc Shoffman Published
-
AstraZeneca’s Covid troubles could see it pull out of making vaccines
News AstraZeneca has suffered a series of setbacks with its Covid-19 jab and may exit the inoculation subsector altogether. Matthew Partridge reports
By Dr Matthew Partridge Published
-
AstraZeneca’s shareholders rebel over pay
News Shareholders in AstraZeneca have rebelled over proposals to raise bonus levels for its bosses.
By Dr Matthew Partridge Last updated
-
If you'd invested in: AstraZeneca and Mitie Group
Features Pharmaceutical giant AstraZeneca is expected to grow its earnings, while outsourcer Mitie's share rice has been hit by a series of profit warnings.
By Alice Gråhns Published
-
Major setback for AstraZeneca
Features Pharma giant AstraZeneca was banking on a key clinical trial for its cancer drugs. It was a flop. What comes next? asks Alice Gråhns.
By Alice Gråhns Published
-
A revolutionary new cancer treatment – and the blue-chip stock set to benefit
Features A new kind of cancer therapy could make a big difference to survival rates - and transform the fortunes of one big UK drugs company. Matthew Partridge explains.
By Dr Matthew Partridge Published
-
AstraZeneca fight rumbles on
News The proposed takeover of AstraZeneca is proving to be one of the most controversial yet.
By Cris Sholto Heaton Published
-
Buy Big Pharma – the deal spree could be just beginning
Features With pharmaceutical stocks still looking cheap and some very smart deals being done, it’s a good time to buy in to the sector. John Stepek explains how.
By John Stepek Published